BioXcel Therapeutics (FRA:BX2) Total Long-Term Liabilities : €113.35 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. BioXcel Therapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was €113.35 Mil.

BioXcel Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for BioXcel Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Total Long-Term Liabilities Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

0.93

1.15

0.98

90.79

94.40

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Liabilities	Get a 7-Day Free Trial															91.85	91.83	95.25	94.40	113.35

BioXcel Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

BioXcel Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines